Moderna: collaboration agreement with Carisma Therapeutics
(CercleFinance.com) - Moderna and Carisma Therapeutics, a specialist in macrophage-based therapies, yesterday announced a strategic collaboration to develop and commercialise in vivo chimeric antigen receptor-modified (CAR-M) monocyte therapies for the treatment of cancer.
In vivo delivery directly to monocytes and macrophages enables a standard therapeutic approach that uses patients' own cells to provide truly personalised treatment, Carisma said.
This aims to develop a new therapeutic approach to cancer treatment by combining Carisma's expertise in macrophage biology with Moderna's pioneering in vivo mRNA delivery technologies.
Under the terms of the agreement, Carisma will receive an upfront cash payment of 45 million dollars and a 35 million dollar convertible bond investment from Moderna.
Copyright (c) 2022 CercleFinance.com. All rights reserved.